2022
Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve
Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve. Journal Of Endourology 2022, 36: 1285-1289. PMID: 35906798, PMCID: PMC9587764, DOI: 10.1089/end.2021.0885.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyShort-term outcomesCase seriesRadical prostatectomyAcceptable short-term outcomesSurgeon 2Average prostate weightLearning curveMedian patient ageClavien-Dindo scaleMedian operating timeTotal postoperative complicationsShorter hospital stayLarge case seriesOperating timeProstate-specific antigenRobotic radical prostatectomyInstitutional review boardSignificant learning curveHospital stayMedian followPostoperative complicationsIntraoperative complicationsPerioperative outcomesBlood loss
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsComparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical prostatectomyAssisted radical prostatectomyConsole timeRadical prostatectomyPrimary treatmentStereotactic body radiation therapyFeasible salvage optionNonsurgical primary treatmentPostoperative pad useUrinary function outcomesRisk of incontinenceKaplan-Meier curvesBody radiation therapyProportional hazards modelLonger console timeT-testStudent's t-testPostoperative complicationsMedian followupOncologic outcomesPerioperative dataBlood lossComplication rateSalvage optionFunction outcomes
2020
Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture
Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture. Nutrition And Cancer 2020, 73: 2740-2750. PMID: 33319628, PMCID: PMC8670097, DOI: 10.1080/01635581.2020.1857412.Peer-Reviewed Original ResearchConceptsVitamin E mixtureProstate tissue levelsUrine samplesReported adverse eventsDay of surgeryProstate cancer patientsPhase 0 trialsDays of supplementationCancer preventive activityAdverse eventsBlood lossTreatment armsUrine levelsCancer patientsRadical prostatectomyAnimal modelsVitamin EProstate tissueTissue levelsPreventive activitiesProstate levelsSupplementationPatientsProstatectomySurgeryRNA-seq profile of African American men with a clinically localized prostate cancer
Nagaya N, Rosenfeld J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer. Prostate International 2020, 9: 125-131. PMID: 34692584, PMCID: PMC8498718, DOI: 10.1016/j.prnil.2020.11.002.Peer-Reviewed Original ResearchProstate cancer tissuesProstate cancerAfrican American menAA menCA menCancer tissuesPotential genetic risk factorSphingosine-1-phosphate signalingAmerican menExpression levelsGenetic risk factorsIngenuity Pathway AnalysisPathway analysisRNA sequencingPoor prognosisBiochemical recurrenceRadical prostatectomyRisk factorsLow expressionCancerMenCaucasiansSignificant differencesPatientsHigh rateObservation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications
Kwon Y, Wang W, Srivastava A, Jang T, Singer E, Parikh R, Kim W, Kim I. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications. Prostate International 2020, 9: 82-89. PMID: 34386450, PMCID: PMC8322776, DOI: 10.1016/j.prnil.2020.10.002.Peer-Reviewed Original ResearchHigh-risk prostate cancerLate radiotherapyDRT groupProstate cancerSurvival outcomesHigh-risk pathologic featuresMultivariable Cox regression modelsCancer-specific survival outcomesFive-year overallPost-RP radiotherapySEER-Medicare analysisMonths of surgeryWorse survival outcomesKaplan-Meier analysisCox regression modelProportion of menCochran-Armitage trend testEarly radiotherapyPathologic featuresRegression modelsStudy cohortERT groupRadical prostatectomyClinical trialsRadiation toxicityThe cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithm
2019
Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? Cancer 2019, 125: 2318-2320. PMID: 30861093, DOI: 10.1002/cncr.32054.Peer-Reviewed Original Research
2018
Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S, Stein M, Mayer T, Ferrari A, Lee N, Parikh R, Ruel N, Kim W, Horie S, Byun S, Ahlering T, Kim I. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate International 2018, 7: 102-107. PMID: 31485434, PMCID: PMC6713798, DOI: 10.1016/j.prnil.2018.10.002.Peer-Reviewed Original ResearchMetastatic prostate cancerCytoreductive radical prostatectomyPhase 1 studyProstate-specific antigenRadical prostatectomyCytoreductive surgeryProstate cancerSpecific antigenDeath 5 monthsAcute tubular necrosisMajor perioperative complicationsOverall complication rateRapid disease progressionDay of surgerySubset of menPerioperative complicationsPrimary endpointTemporary dialysisComplication rateDisseminated diseaseTubular necrosisMajor complicationsMean ageClinical trialsDisease progressionComparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh riskMulti-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance
Dinizo M, Shih W, Kwon Y, Eun D, Reese A, Giusto L, Trabulsi E, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu S, Eggener S, Kim I. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget 2018, 9: 21359-21365. PMID: 29765545, PMCID: PMC5940363, DOI: 10.18632/oncotarget.25103.Peer-Reviewed Original ResearchLow-risk prostate cancerProstate cancerWhite American menActive surveillanceAfrican American menRacial disparitiesRadical prostatectomyProstate cancer active surveillanceActive surveillance eligibilityMulti-institution databaseRisk prostate cancerUnderwent radical prostatectomyActive surveillance criteriaPositive surgical marginsTertiary care institutionSingle-institution studyMulti-institution analysisPotential racial disparitiesSignificant racial disparitiesPercentage cancerOncologic outcomesSurgical marginsHigher BMIProspective studyCancer outcomes
2017
Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy
Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyPT3 prostate cancerRobot-assisted radical prostatectomyPathologic Gleason scoreBiochemical recurrenceRadical prostatectomyClinical progressionProstate cancerLymphovascular invasionRisk stratificationRisk factorsDisease progressionMultivariate Cox proportional regression analysisCox proportional regression analysisAdverse pathologic featuresProportional regression analysisRisk stratification toolMore risk factorsStage pT3bFree survivalOncologic outcomesPathologic featuresStratification toolGleason scoreOptimal patient
2016
Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice
Davis R, Salmasi A, Koprowski C, Kim S, Kwon Y, Faiena I, Patel N, Elsamra S, Kim I. Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice. Clinical Genitourinary Cancer 2016, 14: e617-e622. PMID: 27188968, DOI: 10.1016/j.clgc.2016.04.010.Peer-Reviewed Original ResearchConceptsExtracapsular extensionProstate cancerRadical prostatectomyMp-MRINegative predictive valuePositive predictive valuePredictive valuePartin tablesMultiparametric magnetic resonance imagingNerve-sparing approachPreoperative mp-MRID'Amico risk groupsLarge referral centerHigh-risk groupDatabase of menMagnetic resonance imagingReferral centerStaging modalitiesD'Amico criteriaFusion biopsyOverall prevalenceRisk groupsMultiparametric MRISurgeon's decisionResonance imagingPD03-08 PATHOLOGICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER
Kwon Y, Yu J, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. PD03-08 PATHOLOGICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER. Journal Of Urology 2016, 195: e59. DOI: 10.1016/j.juro.2016.02.2096.Peer-Reviewed Original ResearchChapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications
Salmasi A, Patel N, Kim I. Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications. 2016, 481-489. DOI: 10.1016/b978-0-12-800077-9.00052-9.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate cancerIntermittent androgen deprivation therapyMetastatic prostate cancer treatmentAndrogen-dependent natureProstate cancer treatmentQuality of lifeCost of treatmentDeprivation therapyAdjuvant treatmentMetastatic diseaseADT useAppropriate patientsMetabolic abnormalitiesPalliative optionSignificant complicationsRadical prostatectomyPotential complicationsBone densitySide effectsTreatment settingsOrgan systemsComplicationsOptimal timingCancer treatment
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levelsRefining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score
Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDisease-Free SurvivalHumansKallikreinsKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicProstate-Specific AntigenProstatectomyProstatic NeoplasmsRadiation OncologyRadiotherapy, AdjuvantRetrospective StudiesSocieties, MedicalUnited StatesUrologyConceptsPositive surgical marginsGleason score 6Adjuvant radiotherapyGleason score 8BCR-free survivalRadical prostatectomyBiochemical recurrenceAmerican Urological AssociationPathologic stageGleason scoreScore 6BCR rateSurgical marginsScore 8Urological AssociationPathologic Gleason score 8Multivariate Cox regression analysisPathologic Gleason scoreSurgical margin statusCox regression analysisRadiation Oncology guidelinesAmerican SocietyASTRO guidelineIndependent predictorsMargin statusSafety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of 751 Patients
Modi P, Kwon Y, Patel N, Dinizo M, Farber N, Zhao P, Salmasi A, Parihar J, Ginsberg S, Ha Y, Kim I. Safety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of 751 Patients. Journal Of Endourology 2015, 29: 1148-1151. PMID: 25891967, DOI: 10.1089/end.2015.0094.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyInsufflation pressureComplication rateHemoglobin levelsOperative timeRadical prostatectomyControl groupShort-term perioperative outcomesPostoperative hemoglobin levelsGlomerular filtration rateMean hemoglobin levelDatabase of patientsHigh complication rateNumber of patientsUse of pneumoperitoneumExperimental groupHigh insufflation pressurePerioperative outcomesRenal functionBlood lossPneumoperitoneum pressureFiltration rateSignificant short-term effectPatientsVenous oozingPathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.
Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Urologica E Nefrologica 2015, 67: 1-9. PMID: 25664959.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyRadical prostatectomyActive surveillanceAdvanced diseaseUnderwent robot-assisted radical prostatectomyLow-risk prostate cancerLower prostate volumePSA density levelsLow-risk diseaseActive surveillance cohortOrgan-confined diseaseSpecimens of patientsAdvanced pathologic featuresProspective cohortAdditional patientsPathologic featuresPathologic findingsProstate volumeSingle centerProspective studyGleason scoreSurveillance cohortDefinitive interventionClinicopathological resultsPathologic analysis
2014
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapy